
## **Thomas Damgaard Sandahl**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2302210/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The pathophysiology of Wilson's disease visualized: AÂhuman 64Cu PET study. Hepatology, 2022, 75, 1461-1470.	3.6	15
2	Bis-choline tetrathiomolybdate prevents copper-induced blood–brain barrier damage. Life Science Alliance, 2022, 5, e202101164.	1.3	11
3	The galactose elimination capacity test to monitor liver disease course in patients with Wilson's disease. Scandinavian Journal of Gastroenterology, 2022, , 1-6.	0.6	1
4	Psychometric methods for diagnosing and monitoring minimal hepatic encephalopathy —current validation level and practical use. Metabolic Brain Disease, 2022, 37, 589-605.	1.4	12
5	Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. Journal of Clinical and Translational Hepatology, 2022, 10, 796-802.	0.7	3
6	No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation. Clinical and Translational Gastroenterology, 2021, 12, e00306.	1.3	12
7	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. Scandinavian Journal of Gastroenterology, 2021, 56, 304-311.	0.6	0
8	Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics, 2021, 54, 320-328.	1.9	9
9	Diminished Non-Classical Monocytes in the Blood Associate with Disease Severity in Alcoholic Hepatitis. Clinical and Experimental Gastroenterology, 2021, Volume 14, 259-267.	1.0	3
10	Editorial: metformin for portal hypertension—old dog, new tricks? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 347-347.	1.9	0
11	Designing Clinical Trials in Wilson's Disease. Hepatology, 2021, 74, 3460-3471.	3.6	12
12	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A singleâ€Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. Clinical Pharmacology and Therapeutics, 2021, 110, 1329-1336.	2.3	11
13	Cognitive impairment in stable Wilson disease across phenotype. Metabolic Brain Disease, 2021, 36, 2173-2177.	1.4	4
14	ATP7B variant spectrum in a French pediatric Wilson disease cohort. European Journal of Medical Genetics, 2021, 64, 104305.	0.7	6
15	The Prevalence of Wilson's Disease: An Update. Hepatology, 2020, 71, 722-732.	3.6	103
16	Timeâ€dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful directâ€acting antiviral therapy of chronic hepatitis C. Journal of Viral Hepatitis, 2020, 27, 28-35.	1.0	36
17	Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. American Journal of Physiology - Renal Physiology, 2020, 319, G151-G156.	1.6	2
18	Low Interleukin-22 Binding Protein Is Associated With High Mortality in Alcoholic Hepatitis and Modulates Interleukin-22 Receptor Expression. Clinical and Translational Gastroenterology, 2020, 11, e00197.	1.3	8

#	Article	IF	CITATIONS
19	Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease. Scandinavian Journal of Gastroenterology, 2020, 55, 588-596.	0.6	9
20	The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. Orphanet Journal of Rare Diseases, 2020, 15, 173.	1.2	6
21	Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 15.	1.8	21
22	Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 2020, 26, 2931-2947.	1.4	11
23	Computing the Pathogenicity of Wilson's Disease ATP7B Mutations: Implications for Disease Prevalence. Journal of Chemical Information and Modeling, 2019, 59, 5230-5243.	2.5	10
24	The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode. Journal of Hepatology, 2018, 68, 1330-1331.	1.8	1
25	High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study. Orphanet Journal of Rare Diseases, 2018, 13, 169.	1.2	7
26	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology, 2018, 53, 986-993.	0.6	23
27	Decreased monocyte shedding of the migration inhibitor soluble CD18 in alcoholic hepatitis. Clinical and Translational Gastroenterology, 2018, 9, e160.	1.3	6
28	The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. PLoS ONE, 2017, 12, e0189345.	1.1	32
29	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. Biomarkers in Disease, 2017, , 321-348.	0.0	1
30	The macrophage activation marker <scp>sCD</scp> 163 combined with markers of the Enhanced Liver Fibrosis ( <scp>ELF</scp> ) score predicts clinically significant portal hypertension in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1222-1231.	1.9	34
31	The damageâ€associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation. Apmis, 2016, 124, 741-747.	0.9	15
32	Singleâ€centre experience of the macrophage activation marker soluble (s)CD163 – associations with disease activity and treatment response in patients with autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 1062-1070.	1.9	33
33	Editorial: measuring inflammatory and fibrotic components of portal hypertension – a nonâ€invasive hepatic venous pressure gradient? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 205-206.	1.9	0
34	Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center. Acta Radiologica, 2016, 57, 844-851.	0.5	6
35	Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis. Journal of Pharmaceutical and Biomedical Analysis, 2016, 122, 141-147.	1.4	16
36	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. Biomarkers in Disease, 2016, , 1-28.	0.0	2

#	Article	IF	CITATIONS
37	Cytotoxic T lymphocytes and natural killer cells display impaired cytotoxic functions and reduced activation in patients with alcoholic hepatitis. American Journal of Physiology - Renal Physiology, 2015, 308, G269-G276.	1.6	25
38	Circulating mannanâ€binding lectin, Mâ€; Lâ€; Hâ€ficolin and collectinâ€liverâ€1 levels in patients with acute liver failure. Liver International, 2015, 35, 756-763.	1.9	20
39	Blood culture-positive infections in patients with alcoholic hepatitis. Scandinavian Journal of Infectious Diseases, 2014, 46, 902-905.	1.5	11
40	A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clinical Chemistry and Laboratory Medicine, 2014, 52, 453-461.	1.4	79
41	Short-term and Long-term Causes of Death in Patients With Alcoholic Hepatitis in Denmark. Clinical Gastroenterology and Hepatology, 2014, 12, 1739-1744.e1.	2.4	44
42	Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study. American Journal of Gastroenterology, 2014, 109, 1749-1756.	0.2	81
43	The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-1± therapy. Journal of Crohn's and Colitis, 2014, 8, 521-528.	0.6	9
44	Changes in the Levels of Mannan-Binding Lectin and Ficolins During Head-Down Tilted Bed Rest. Aviation, Space, and Environmental Medicine, 2014, 85, 805-811.	0.6	1
45	Alcoholic hepatitis. Danish Medical Journal, 2014, 61, B4755.	0.5	9
46	Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. Journal of Crohn's and Colitis, 2013, 7, 248-255.	0.6	50
47	Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course. PLoS ONE, 2013, 8, e55101.	1.1	26
48	Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. Clinical Nutrition, 2012, 31, 940-945.	2.3	17
49	Soluble <scp>CD</scp> 163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2012, 36, 173-180.	1.9	132
50	Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: A nationwide population based cohort study. Journal of Hepatology, 2011, 54, 760-764.	1.8	130
51	Effects of insulinâ€like growth factorâ€l administration on <i>in vivo</i> regulation of urea synthesis in normal subjects and patients with cirrhosis. Liver International, 2011, 31, 132-137.	1.9	9
52	Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut, 2011, 60, 1389-1393.	6.1	111
53	Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scandinavian Journal of Gastroenterology, 2011, 46, 1127-1132.	0.6	45
54	Tumor necrosis factor-α acutely up-regulates urea synthesis in vivo in rats – a hepatic component of inflammatory catabolism?. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 151-157.	0.6	10